On Friday shares of Cooper-Standard Holdings Inc. (NYSE:CPS) closed at $63.80. Company’s sales growth for last 5 years was 10.80%. On May 07, Cooper-Standard Holdings Inc. (NYSE:CPS) reported net income of $21.0 million, or $1.15 per diluted share, and adjustedRead More
On Thursday shares of Oi SA (ADR) (NYSE:OIBR) closed at $1.86. Company’s sales growth for last 5 years was 19.70%. Oi SA (ADR) (NYSE:OIBR) delivered significantly better results in 1Q, 15 with improvement in virtually all trends. We are reiteratingRead More
On Wednesday shares of Vale S.A. (NYSE:VALE) closed at $8.19. Company’s sales growth for last 5 years was 10.00% and EPS growth for next 5 years is recorded as 0.01%. Vale S.A. (NYSE:VALE) said it could reduce forecasted iron oreRead More
On Monday shares of Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN) closed at $9.41. Company’s EPS growth for next 5 years is recorded as 17.58%. Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN) on 25 April, presented two late breaker posters at the 50th Annual Meeting ofRead More
On Thursday shares of Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN) closed at $10.19. Company’s EPS growth for next 5 years is recorded as 17.58%. Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN) carries Zacks Rank #4 (Sell). On last trading day Ericsson (NASDAQ:ERIC) moved up 0.08%Read More
On Thursday shares of Barrick Gold Corporation (NYSE:ABX) closed at $11.29. Company’s sales growth for last 5 years was 4.70% and EPS growth for next 5 years is recorded as 13.40%. On March 24, Barrick Gold Corporation (NYSE:ABX) announced thatRead More
On Wednesday shares of ZIOPHARM Oncology, Inc. (NASDAQ:ZIOP) closed at $11.05. Zacks reaffirmed their hold rating on shares of ZIOPHARM Oncology (NASDAQ:ZIOP) in a report issued on Sunday. Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN) in last trading activity moved down -3.69% toRead More
On Tuesday shares of BioTime, Inc. (NYSEMKT:BTX) closed at $5.46. Company’s sales growth for last 5 years was 22.30%. BioTime, Inc. (NYSEMKT:BTX) and its subsidiary OncoCyte Corporation on 20 March 2015, announced the online availability of abstracts providing human clinicalRead More
Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN) announced Thursday that it will begin clinical trials with both drugs for Hepatitis-C patients some time in the first half of 2015. These trials will last between six weeks to three months, with results expected inRead More
Needham & Company LLC reiterated their hold rating on shares of VIVUS (NASDAQ:VVUS) in a research report sent to investors on 25 February 2015. On Friday shares of VIVUS Inc. (NASDAQ:VVUS) closed at $2.79. Company’s sales growth for last 5Read More
